Orchard Therapeutics plc - ADR

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Orchard Therapeutics plc (NASDAQ: ORTX) to Kyowa Kirin Co., Ltd. is fair to Orchard shareholders. Under the terms of the agreement, Kyowa Kirin would acquire all Orchard's American Depositary Shares (ADS) at a price of $16.00 per ADS in cash. Additionally, a non-transferable contingent value right will be distributed to Orchard shareholders, entitling the holders to a cash payment of $.

ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders

Shares of Orchard Therapeutics doubled in pre-market trading following the announcement that Japan-based pharmaceutical company Kyowa Kirin will acquire the gene therapy leader for approximately $477.6 million. The acquisition price is set at $16.00 per American Depositary Share (ADS) in cash, with investors receiving and additional $1.00 per ADS if certain conditions are met.

Orchard Therapeutics shares double following Japanese bid approach

Orchard Therapeutics (NASDAQ: ORTX ) stock is rocketing higher on Thursday after the gene therapy company announced an acquisition deal. Kyowa Kirin has agreed to acquire Orchard Therapeutics for $387.4 million.

Why Is Orchard Therapeutics (ORTX) Stock Up 98% Today?

Orchard Therapeutics shares ORTX, -0.61% nearly doubled, to $15.79, after agreeing to be purchased by Japan's Kyowa Kirin 4151, -0.24% for at least $16 per share in cash, plus an additional contingent value right of $1 per share. The total consideration will be as much as $478 million.

Orchard Therapeutics shares nearly double on buyout deal

Japanese pharmaceutical firm Kyowa Kirin said on Thursday it would acquire Britain-based biopharmaceutical company Orchard Therapeutics for $477.6 million, aiming to promote the development of new drugs.

Kyowa Kirin to acquire Orchard Therapeutics for $478 mln

-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases- -Acquisition enriches Kyowa Kirin's portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy ® (atidarsagene autotemcel)- -Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million- -Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST-

Kyowa Kirin to Acquire Orchard Therapeutics

Orchard Therapeutics PLC Sponsored ADR (ORTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?

Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.

Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up

Orchard Therapeutics plc is a London-based biotech company focused on developing gene therapies for rare diseases. The company's lead therapy, OTL-200, has received marketing authorization in Europe for the treatment of metachromatic leukodystrophy. Orchard's stock has suffered a significant decline, but there is potential for a rebound if OTL-200 receives FDA approval.

Orchard Therapeutics: A Reassessment

PDUFA date set for March 18, 2024 OTL-200 would be the first and only treatment in the U.S. for early-onset MLD Previously published data demonstrated administration of one-time gene therapy enables sustained preservation of motor function and cognitive development BOSTON and LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority Review.

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review

Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 12 years of follow-up (median 6.76 years)

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023

The consensus price target hints at a 365% upside potential for Orchard Therapeutics PLC Sponsored ADR (ORTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Orchard Therapeutics PLC Sponsored ADR (ORTX) Could Surge 365.03%: Read This Before Placing a Bet

Orchard Therapeutics plc (NASDAQ:ORTX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Bobby Gaspar - Chief Executive Officer Frank Thomas - President and COO Braden Parker - Chief Commercial Officer Conference Call Participants Robert Finke - Guggenheim Securities Pete Stavropoulos - Cantor Fitzgerald Brendan Smith - TD Cowen Operator Good day and thank you for standing by. Welcome to the Orchard Therapeutic Second Quarter 2023 Earnings Conference Call.

Orchard Therapeutics plc (ORTX) Q2 2023 Earnings Call Transcript

Reported $6.6M in Q2'23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously estimated in the medical literature Six presentations at ASGCT demonstrate the ability of HSC gene therapy to address neurometabolic and CNS disorders, as well as larger indications Company to host conference call and live webcast today at 8:00 a.m. EDT BOSTON and LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced several business accomplishments along with its financial results for the quarter ended June 30, 2023.

Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

BOSTON and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, expresses its strong appreciation for the passage of the Newborn Metabolic Screening Act in Illinois, also known as SB67. The law, anticipated to go into effect in January 2024, mandates the expansion of the Illinois Department of Public Health's Newborn Screening program to include metachromatic leukodystrophy (MLD) for the estimated 130,000 newborns in the state each year. Illinois becomes the first state in the U.S. to add newborn screening for MLD to its statewide panel.

Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel

BOSTON and LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2023, at 8:00 a.m. EDT to review business updates and its second quarter 2023 financial results.

Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results

Funding from second closing extends cash runway to mid-2025 to advance the company's HSC gene therapy portfolio through several potential value-creating milestones

Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital

BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at Stifel's Inaugural Genetic Medicines Day on Tuesday, May 30, 2023 at 5:00 p.m. EDT.

Orchard Therapeutics to Present at Stifel's Genetic Medicines Day

New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of motor skills

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn's disease, a severe and treatment-refractory form of the disease

Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications

OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients treated expected to grow year-over-year in 2023 New clinical data in MPS-I and MPS-IIIA and pre-clinical data in genetic subsets of frontotemporal dementia and Crohn's to be presented this week at ASGCT Closed initial $34M of potential $188M in proceeds as part of strategic financing and ended Q1 2023 with $146M of cash and investments and runway into 2025 BOSTON and LONDON, May 15, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced various business accomplishments along with its financial results for the quarter ended March 31, 2023. “Following multiple productive interactions this year with the FDA on our clinical and CMC packages, I am delighted to announce the initiation of our OTL-200 rolling BLA submission with the filing of the first module,” said Bobby Gaspar, M.D.

Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA

Orchard Therapeutics PLC Sponsored ADR (ORTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ORTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Orchard Therapeutics PLC Sponsored ADR (ORTX) Now Trades Above Golden Cross: Time to Buy?

Six presentations showcase the differentiated profile and broad applicability of the company's HSC gene therapy platform

Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023

Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates.

Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates

BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the Guggenheim Genomic Medicines and Rare Disease Day on Tuesday, April 4, 2023 at 1:35pm ET.

News for Orchard Therapeutics plc - ADR Stock (ORTX)